Suppr超能文献

新型冠状病毒肺炎患者复发性呼吸机相关性肺炎的发病率、结局及危险因素:一项回顾性多中心研究

Incidence, Outcomes and Risk Factors of Recurrent Ventilator Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study.

作者信息

Gragueb-Chatti Ines, Hyvernat Hervé, Leone Marc, Agard Geoffray, Peres Noémie, Guervilly Christophe, Boucekine Mohamed, Hamidi Dany, Papazian Laurent, Dellamonica Jean, Lopez Alexandre, Hraiech Sami

机构信息

Service de Médecine Intensive-Réanimation, AP-HM, Hôpital Nord, 13015 Marseille, France.

Service de Médecine Intensive-Réanimation, CHU Nice, 06202 Nice, France.

出版信息

J Clin Med. 2022 Nov 30;11(23):7097. doi: 10.3390/jcm11237097.

Abstract

Background: High incidence of ventilator associated pneumonia (VAP) has been reported in critically ill patients with COVID-19. Among these patients, we aimed to assess the incidence, outcomes and risk factors of VAP recurrences. Methods: We conducted an observational retrospective study in three French intensive care units (ICUs). Patients admitted for a documented COVID-19 from March 2020 to May 2021 and requiring mechanical ventilation (MV) for ≥48 h were included. The study main outcome was the incidence of VAP recurrences. Secondary outcomes were the duration of MV, ICU and hospital length of stay and mortality according to VAP and recurrences. We also assessed the factors associated with VAP recurrences. Results: During the study period, 398 patients met the inclusion criteria. A total of 236 (59%) of them had at least one VAP episode during their ICU stay and 109 (46%) of these patients developed at least one recurrence. The incidence of VAP recurrence considering death and extubation as competing events was 29.6% (IC = [0.250−0.343]). Seventy-eight percent of recurrences were due to the same bacteria (relapses). Patients with a VAP recurrence had a longer duration of MV as compared with one VAP and no VAP patients (41 (25−56) vs. 16 (8−30) and 10 (5−18) days; p < 0.001) and a longer ICU length of stay (46 (29−66) vs. 22 (12−36) and 14 (9−25) days; p < 0.001). The 90-day mortality was higher in the recurrence group as compared with the no VAP group only (31.2 vs. 21.0% (p = 0.021)). In a multivariate analysis including bacterial co-infection at admission, the use of immunosuppressive therapies and the bacteria responsible for the first VAP episode, the duration of MV was the only factor independently associated with VAP recurrence. Conclusion: In COVID-19 associated respiratory failure, recurrences affected 46% of patients with a first episode of VAP. VAP recurrences were mainly relapses and were associated with a prolonged duration of MV and ICU length of stay but not with a higher mortality. MV duration was the only factor associated with recurrences.

摘要

背景

据报道,新型冠状病毒肺炎(COVID-19)危重症患者中呼吸机相关性肺炎(VAP)的发病率较高。在这些患者中,我们旨在评估VAP复发的发生率、结局及危险因素。方法:我们在法国的三个重症监护病房(ICU)进行了一项观察性回顾性研究。纳入2020年3月至2021年5月因确诊COVID-19入院且需要机械通气(MV)≥48小时的患者。研究的主要结局是VAP复发的发生率。次要结局是MV持续时间、ICU和住院时间以及根据VAP和复发情况的死亡率。我们还评估了与VAP复发相关的因素。结果:在研究期间,398例患者符合纳入标准。其中共有236例(59%)在ICU住院期间至少发生1次VAP事件,这些患者中有109例(46%)至少发生1次复发。将死亡和拔管视为竞争事件时,VAP复发的发生率为29.6%(IC = [0.250 - 0.343])。78%的复发是由同一细菌引起的(再发)。与发生1次VAP和未发生VAP的患者相比,发生VAP复发的患者MV持续时间更长(41(25 - 56)天 vs. 16(8 - 30)天和10(5 - 18)天;p < 0.001),ICU住院时间更长(46(29 - 66)天 vs. 22(12 - 36)天和14(9 - 25)天;p < 0.001)。仅与未发生VAP的组相比,复发组的90天死亡率更高(31.2% vs. 21.0%(p = 0.021))。在一项多变量分析中,纳入入院时的细菌合并感染、免疫抑制治疗的使用以及首次VAP事件所涉及的细菌,MV持续时间是唯一与VAP复发独立相关的因素。结论:在COVID-19相关呼吸衰竭中,复发影响了46%首次发生VAP的患者。VAP复发主要是再发,与MV持续时间延长和ICU住院时间延长相关,但与更高的死亡率无关。MV持续时间是与复发相关的唯一因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/9738672/63601211c48d/jcm-11-07097-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验